Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Asthma is a common, serious illness among children in the United States. While a low dose of
inhaled corticosteroids (ICS) may effectively control symptoms, some children may require
additional medications to maintain adequate asthma control. This study compares the
effectiveness of a higher dose of ICS, ICS combined with a long-acting beta-agonist (LABA)
medication, and ICS combined with a leukotriene receptor antagonist (LTRA) medication at
reducing the impact and severity of asthma exacerbations that occur in children with mild to
moderate persistent asthma.
Phase:
Phase 3
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Montelukast Salmeterol Xinafoate Xhance